CD4+ CD52lo T-cell expression contributes to the development of systemic lupus erythematosus

CD4+ CD52lo T-cell expression contributes to the development of systemic lupus erythematosus

Copyright © 2017 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 187(2018) vom: 01. Feb., Seite 50-57
1. Verfasser: Umeda, Masataka (VerfasserIn)
Weitere Verfasser: Koga, Tomohiro, Ichinose, Kunihiro, Igawa, Takashi, Sato, Tomohito, Takatani, Ayuko, Shimizu, Toshimasa, Fukui, Shoichi, Nishino, Ayako, Horai, Yoshiro, Hirai, Yasuko, Kawashiri, Shin-Ya, Iwamoto, Naoki, Aramaki, Toshiyuki, Tamai, Mami, Nakamura, Hideki, Yamamoto, Kazuo, Abiru, Norio, Origuchi, Tomoki, Ueki, Yukitaka, Kawakami, Atsushi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't CD52 Systemic lupus erythematosus T cells Antibodies, Antinuclear Autoantibodies CCL17 protein, human CCR8 protein, human CD52 Antigen mehr... CD52 protein, human Chemokine CCL17 Immunoglobulin G Receptors, CCR8
LEADER 01000naa a22002652 4500
001 NLM277003636
003 DE-627
005 20231225013234.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2017.10.004  |2 doi 
028 5 2 |a pubmed24n0923.xml 
035 |a (DE-627)NLM277003636 
035 |a (NLM)29031579 
035 |a (PII)S1521-6616(17)30567-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Umeda, Masataka  |e verfasserin  |4 aut 
245 1 0 |a CD4+ CD52lo T-cell expression contributes to the development of systemic lupus erythematosus 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.03.2019 
500 |a Date Revised 18.03.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2017 Elsevier Inc. All rights reserved. 
520 |a The cell-surface glycoprotein CD52 is widely expressed in lymphocytes. CD4+CD52hi T cells are functioning suppressor CD4+T cells. We investigated the role of the immune regulation of CD4+CD52 T cells in systemic lupus erythematosus (SLE). CD4+CD52lo T cells were increased in SLE patients, in positive correlation with SLEDAI, anti-ds-DNA antibody, and IgG concentration. Circulating follicular helper-like T cells (Tfh-like cells) were also increased in SLE, in positive correlation with CD4+CD52lo T cells. Chemokine receptor 8 (CCR8) expression in CD4+CD52lo T cells was increased. In vitro experiments using CD4 T cells of SLE patients showed that thymus and activation-regulated chemokine (TARC), a ligand of CCR8, contributed to the development of CD4+CD52hi T cells into CD4+CD52lo T cells. Our findings suggest that CD4+CD52lo T-cell upregulation is involved in the production of pathogens by autoantibodies, and TARC may contribute to the development of SLE through an aberrant induction of CD4+CD52lo T cells 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a CD52 
650 4 |a Systemic lupus erythematosus 
650 4 |a T cells 
650 7 |a Antibodies, Antinuclear  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a CCL17 protein, human  |2 NLM 
650 7 |a CCR8 protein, human  |2 NLM 
650 7 |a CD52 Antigen  |2 NLM 
650 7 |a CD52 protein, human  |2 NLM 
650 7 |a Chemokine CCL17  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Receptors, CCR8  |2 NLM 
700 1 |a Koga, Tomohiro  |e verfasserin  |4 aut 
700 1 |a Ichinose, Kunihiro  |e verfasserin  |4 aut 
700 1 |a Igawa, Takashi  |e verfasserin  |4 aut 
700 1 |a Sato, Tomohito  |e verfasserin  |4 aut 
700 1 |a Takatani, Ayuko  |e verfasserin  |4 aut 
700 1 |a Shimizu, Toshimasa  |e verfasserin  |4 aut 
700 1 |a Fukui, Shoichi  |e verfasserin  |4 aut 
700 1 |a Nishino, Ayako  |e verfasserin  |4 aut 
700 1 |a Horai, Yoshiro  |e verfasserin  |4 aut 
700 1 |a Hirai, Yasuko  |e verfasserin  |4 aut 
700 1 |a Kawashiri, Shin-Ya  |e verfasserin  |4 aut 
700 1 |a Iwamoto, Naoki  |e verfasserin  |4 aut 
700 1 |a Aramaki, Toshiyuki  |e verfasserin  |4 aut 
700 1 |a Tamai, Mami  |e verfasserin  |4 aut 
700 1 |a Nakamura, Hideki  |e verfasserin  |4 aut 
700 1 |a Yamamoto, Kazuo  |e verfasserin  |4 aut 
700 1 |a Abiru, Norio  |e verfasserin  |4 aut 
700 1 |a Origuchi, Tomoki  |e verfasserin  |4 aut 
700 1 |a Ueki, Yukitaka  |e verfasserin  |4 aut 
700 1 |a Kawakami, Atsushi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 187(2018) vom: 01. Feb., Seite 50-57  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:187  |g year:2018  |g day:01  |g month:02  |g pages:50-57 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2017.10.004  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 187  |j 2018  |b 01  |c 02  |h 50-57